COVID-19 With Preexisting Hypercoagulability Digestive Disease

COVID-19 With Preexisting Hypercoagulability Digestive Disease

Hu Zhang, Silan Shen, Hu Zhang, Jingxi Mu, Mingshan Jiang, Mingshan Jiang, Mingshan Jiang, Jingxi Mu, Jingxi Mu, Silan Shen, Silan Shen, Hu Zhang

The outbreak of coronavirus disease of 2019 (COVID-19) has become a global public health and economic crisis. The advent of hypercoagulability and thrombotic complications can substantially influence the prognosis of COVID-19 patients. In this review, we elaborate on the clinical findings, potential underlying pathogenesis, and therapeutic strategy of hypercoagulability and thromboembolism in COVID-19, particularly focusing on the COVID-19 patients with preexisting digestive hypercoagulability disease.

2021

SARS-CoV-2, Coronavirus disease 2019, inflammatory bowel disease, thromboembolism, Hypercoagulability

10.3389/fmed.2020.587350

Epidemiology and Health

Korean Society of Epidemiology

Medicine (General)